SOLIGENIX INC (SNGX)
US8342236044 - Common Stock
Taking everything into account, SNGX scores 3 out of 10 in our fundamental rating. SNGX was compared to 561 industry peers in the Biotechnology industry. SNGX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SNGX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year SNGX has reported negative net income.
SNGX had a negative operating cash flow in the past year.
SNGX had negative earnings in each of the past 5 years.
In the past 5 years SNGX always reported negative operating cash flow.
1.2 Ratios
SNGX's Return On Assets of -67.76% is on the low side compared to the rest of the industry. SNGX is outperformed by 65.05% of its industry peers.
SNGX has a Return On Equity of -119.61%. This is comparable to the rest of the industry: SNGX outperforms 40.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.76% | ||
| ROE | -119.61% | ||
| ROIC | N/A |
ROA(3y)-68.67%
ROA(5y)-83.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SNGX has a better Gross Margin (6.39%) than 73.15% of its industry peers.
SNGX's Gross Margin has been stable in the last couple of years.
SNGX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 6.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.28%
GM growth 5Y-1.04%
2. Health
2.1 Basic Checks
SNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SNGX has been reduced compared to 1 year ago.
Compared to 5 years ago, SNGX has less shares outstanding
Compared to 1 year ago, SNGX has an improved debt to assets ratio.
2.2 Solvency
SNGX has an Altman-Z score of -31.56. This is a bad value and indicates that SNGX is not financially healthy and even has some risk of bankruptcy.
SNGX has a worse Altman-Z score (-31.56) than 91.35% of its industry peers.
There is no outstanding debt for SNGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -31.56 |
ROIC/WACCN/A
WACC11.02%
2.3 Liquidity
A Current Ratio of 2.28 indicates that SNGX has no problem at all paying its short term obligations.
With a Current ratio value of 2.28, SNGX is not doing good in the industry: 73.51% of the companies in the same industry are doing better.
A Quick Ratio of 2.28 indicates that SNGX has no problem at all paying its short term obligations.
With a Quick ratio value of 2.28, SNGX is not doing good in the industry: 71.89% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.28 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 89.84% over the past year.
The Revenue for SNGX has decreased by -62.46% in the past year. This is quite bad
The Revenue for SNGX have been decreasing by -30.67% on average. This is quite bad
EPS 1Y (TTM)89.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.53%
Revenue 1Y (TTM)-62.46%
Revenue growth 3Y-29.15%
Revenue growth 5Y-30.67%
Sales Q2Q%-100%
3.2 Future
Based on estimates for the next years, SNGX will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.78% on average per year.
SNGX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.11% yearly.
EPS Next Y62.08%
EPS Next 2Y29.12%
EPS Next 3Y18.78%
EPS Next 5YN/A
Revenue Next Year-36.11%
Revenue Next 2Y6.23%
Revenue Next 3Y4.11%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SNGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SNGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SNGX's earnings are expected to grow with 18.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.12%
EPS Next 3Y18.78%
5. Dividend
5.1 Amount
No dividends for SNGX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SOLIGENIX INC
NASDAQ:SNGX (1/8/2025, 8:00:01 PM)
After market: 3.26 -0.01 (-0.31%)3.27
-0.32 (-8.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners4.4%
Inst Owner Change0%
Ins Owners0.02%
Ins Owner Change0%
Market Cap8.21M
Analysts82.86
Price Target22.95 (601.83%)
Short Float %1.77%
Short Ratio0.9
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.74%
Min EPS beat(2)27.64%
Max EPS beat(2)29.84%
EPS beat(4)3
Avg EPS beat(4)12.24%
Min EPS beat(4)-15.64%
Max EPS beat(4)29.84%
EPS beat(8)6
Avg EPS beat(8)-9.56%
EPS beat(12)8
Avg EPS beat(12)-9.34%
EPS beat(16)11
Avg EPS beat(16)-5.17%
Revenue beat(2)0
Avg Revenue beat(2)-99.43%
Min Revenue beat(2)-100%
Max Revenue beat(2)-98.85%
Revenue beat(4)0
Avg Revenue beat(4)-61.72%
Min Revenue beat(4)-100%
Max Revenue beat(4)-5.39%
Revenue beat(8)3
Avg Revenue beat(8)-21%
Revenue beat(12)6
Avg Revenue beat(12)0.67%
Revenue beat(16)6
Avg Revenue beat(16)-13.3%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-375%
EPS NY rev (1m)0%
EPS NY rev (3m)3.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 22.54 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.38 | ||
| P/tB | 1.38 | ||
| EV/EBITDA | N/A |
EPS(TTM)-8.65
EYN/A
EPS(NY)-5.17
Fwd EYN/A
FCF(TTM)-3.19
FCFYN/A
OCF(TTM)-3.19
OCFYN/A
SpS0.15
BVpS2.36
TBVpS2.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.76% | ||
| ROE | -119.61% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 6.39% | ||
| FCFM | N/A |
ROA(3y)-68.67%
ROA(5y)-83.05%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.28%
GM growth 5Y-1.04%
F-Score3
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.28 | ||
| Altman-Z | -31.56 |
F-Score3
WACC11.02%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.53%
EPS Next Y62.08%
EPS Next 2Y29.12%
EPS Next 3Y18.78%
EPS Next 5YN/A
Revenue 1Y (TTM)-62.46%
Revenue growth 3Y-29.15%
Revenue growth 5Y-30.67%
Sales Q2Q%-100%
Revenue Next Year-36.11%
Revenue Next 2Y6.23%
Revenue Next 3Y4.11%
Revenue Next 5YN/A
EBIT growth 1Y13.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y33.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.82%
OCF growth 3YN/A
OCF growth 5YN/A